717 related articles for article (PubMed ID: 21705286)
1. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
2. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
[TBL] [Abstract][Full Text] [Related]
3. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
4. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
Danila DC; Heller G; Gignac GA; Gonzalez-Espinoza R; Anand A; Tanaka E; Lilja H; Schwartz L; Larson S; Fleisher M; Scher HI
Clin Cancer Res; 2007 Dec; 13(23):7053-8. PubMed ID: 18056182
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors.
Goodman OB; Fink LM; Symanowski JT; Wong B; Grobaski B; Pomerantz D; Ma Y; Ward DC; Vogelzang NJ
Cancer Epidemiol Biomarkers Prev; 2009 Jun; 18(6):1904-13. PubMed ID: 19505924
[TBL] [Abstract][Full Text] [Related]
6. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
8. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
9. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
Sasaki T; Onishi T; Hoshina A
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
11. Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancer.
Chang K; Kong YY; Dai B; Ye DW; Qu YY; Wang Y; Jia ZW; Li GX
Oncotarget; 2015 Dec; 6(39):41825-36. PubMed ID: 26497689
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer.
Hou JM; Krebs MG; Lancashire L; Sloane R; Backen A; Swain RK; Priest LJ; Greystoke A; Zhou C; Morris K; Ward T; Blackhall FH; Dive C
J Clin Oncol; 2012 Feb; 30(5):525-32. PubMed ID: 22253462
[TBL] [Abstract][Full Text] [Related]
13. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of circulating tumor cell count in patients with metastatic hormone-sensitive prostate cancer.
Resel Folkersma L; San José Manso L; Galante Romo I; Moreno Sierra J; Olivier Gómez C
Urology; 2012 Dec; 80(6):1328-32. PubMed ID: 23063057
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
17. Epithelial cell adhesion molecule-positive circulating tumor cells as predictive biomarker in patients with prostate cancer.
Amato RJ; Melnikova V; Zhang Y; Liu W; Saxena S; Shah PK; Jensen BT; Torres KE; Davis DW
Urology; 2013 Jun; 81(6):1303-7. PubMed ID: 23622774
[TBL] [Abstract][Full Text] [Related]
18. A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy.
Lv W; Shang H; Pei X; Chen Y; Xie H; He D; Wang X; Li L
Int Urol Nephrol; 2017 Jan; 49(1):61-67. PubMed ID: 27837416
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]